New clinical results show that Durvalumab improved survival (versus a placebo) in patients with non–small cell lung cancer.

Data from the trial may be added to the Imfinzi label, and suggests an important role for Imfinzi in this setting.

Read the results from the trial and more information in this Onclive article.